PHILADELPHIA--(

费城--(

BUSINESS WIRE

商业热线

)--

)--

Aro Biotherapeutics

Aro生物治疗

, a clinical-stage biotechnology company working to develop potent, tissue-targeted medicines, today announced the appointment of Glenn D. Crater, MD, as chief medical officer (CMO). Dr. Crater will lead the development of Aro’s pipeline of Centyrin-based, tissue-targeted medications, including the company’s lead product candidate ABX1100, a novel potential treatment for Pompe disease..

，一家致力于开发有效的组织靶向药物的临床阶段生物技术公司，今天宣布任命医学博士GlennD.Crater为首席医疗官（CMO）。Crater博士将领导Aro基于百岁蛋白的组织靶向药物管道的开发，包括该公司的主要候选产品ABX1100，这是一种治疗庞贝病的新型潜在疗法。。

“Dr. Crater joins our team at an opportune time, with our lead product, ABX1100, in early-stage development for patients with late-onset Pompe disease,” said Susan Dillon, PhD, co-founder, president and chief executive officer of Aro. “Glenn is a proven leader in our industry, with deep and broad experience in clinical development.

Aro联合创始人、总裁兼首席执行官苏珊·狄龙博士（SusanDillon）说：“陨石坑博士（Dr.Crater）适时加入了我们的团队，我们的主导产品ABX1100正在为迟发性庞贝病患者进行早期开发。”。“Glenn是我们行业公认的领导者，在临床开发方面拥有丰富的经验。

We are thrilled to have him on board to help us advance ABX1100 and guide our other development programs.”.

我们很高兴有他加入，帮助我们推进ABX1100，并指导我们的其他发展计划。”。

“Aro Biotherapeutics has demonstrated a mastery of cutting-edge technology in their ability to deliver tissue-targeted siRNA therapies. I am excited to join the company just as ABX1100 enters the clinic in Pompe disease, a debilitating and deadly disease for which there are limited treatment options,” commented Dr.

“Aro Biotherapeutics在提供组织靶向siRNA治疗的能力方面展示了对尖端技术的掌握。当ABX1100进入庞贝病的诊所时，我很高兴加入该公司，庞贝病是一种衰弱致命的疾病，治疗选择有限，”Dr。

Crater. “In addition, I am eager to help Aro advance the development of protein-linked siRNA therapies for other diseases where traditional approaches have not been successful.”.

火山口。“此外，我渴望帮助Aro推进蛋白质连接的siRNA疗法的发展，以治疗传统方法尚未成功的其他疾病。”。

Dr. Crater joins Aro from Inversago Pharma, where he served as CMO, with responsibility for the company’s medical and clinical programs, including the development of cannabinoid receptor inverse agonists for the treatment of metabolic and fibrotic diseases, leading to the company’s successful acquisition by Novo Nordisk.

Crater博士加入了来自Inversago Pharma的Aro，在那里他担任CMO，负责公司的医疗和临床计划，包括开发用于治疗代谢和纤维化疾病的大麻素受体反向激动剂，从而导致该公司被诺和诺德成功收购。

Previously, at Theravance Biopharma, Dr. Crater was respiratory portfolio head and vice president of clinical development and medical affairs..

此前，在Theravance Biopharma，Crater博士是呼吸投资组合负责人兼临床开发和医疗事务副总裁。。

At Aerocrine AB, where he served as vice president of global clinical development and medical affairs, Dr. Crater initiated and led the development of a new medical device for the treatment of asthma and rare diseases. Earlier in his career, Dr. Crater was director of clinical development at GlaxoSmithKline, where he invented and spearheaded the development of dual bronchodilator therapy for the treatment of chronic obstructive pulmonary disease (COPD).

在Aerocrine AB担任全球临床开发和医疗事务副总裁期间，Crater博士启动并领导了一种用于治疗哮喘和罕见疾病的新型医疗设备的开发。在职业生涯的早期，Crater博士是葛兰素史克公司的临床开发总监，他在那里发明并率先开发了用于治疗慢性阻塞性肺疾病（COPD）的双重支气管扩张剂疗法。

He also served as country medical director for GlaxoSmithKline Canada, where he built and directed a division comprising medical affairs, medical science liaisons, clinical studies, pharmacovigilance, medical information, medical education, and health economics and outcomes research..

他还曾担任葛兰素史克加拿大公司的国家医疗主管，在那里他建立并领导了一个部门，包括医疗事务、医学科学联络、临床研究、药物警戒、医学信息、医学教育以及卫生经济学和成果研究。。

Dr. Crater is also the founder of Clinical Pharma Specialist Consultants, LLC, a firm that provides expertise in clinical trial design, pharmaceutical development, medical affairs, risk management, and other functions to small pharmaceutical companies. Prior to his industry roles, he was a practicing pulmonologist and critical care physician.

Crater博士也是Clinical Pharma Specialist Consultants，LLC的创始人，该公司为小型制药公司提供临床试验设计、药物开发、医疗事务、风险管理和其他功能方面的专业知识。在担任行业角色之前，他是一名执业肺科医生和重症监护医生。

Dr. Crater holds 14 patents and is the author or co-author of more than 50 scientific publications in the peer-reviewed literature. He received his Doctor of Medicine degree from the University of Tennessee and holds a Bachelor of Science in Biology and Religion from Wake Forest University..

Crater博士拥有14项专利，是同行评审文献中50多篇科学出版物的作者或合著者。他在田纳西大学获得医学博士学位，并在维克森林大学获得生物学和宗教理学学士学位。。

About ABX1100

关于ABX1100

ABX1100, an investigational treatment for Pompe disease, is comprised of a CD71 receptor-binding Centyrin conjugated to a small interfering RNA (siRNA) that specifically interferes with expression of

ABX1100是庞贝氏病的一种研究性治疗方法，由CD71受体结合的百岁蛋白与小干扰RNA（siRNA）结合而成，该小干扰RNA特异性干扰庞贝氏病的表达

GYS1

健身房1

messenger RNA (mRNA), thereby reducing levels and overall activity of the GYS1 enzyme in muscle tissues. ABX1100 was well tolerated in a recently completed Phase 1a trial conducted in normal healthy volunteers, and demonstrated durable

信使RNA（mRNA），从而降低肌肉组织中GYS1酶的水平和总体活性。在最近完成的一项在正常健康志愿者中进行的1a期试验中，ABX1100的耐受性良好，并且表现出持久性

GYS1

健身房1

mRNA knockdown in muscle biopsies, supporting the potential for quarterly dosing. ABX1100 has received Orphan Drug Designation and Rare Pediatric Disease status from the United States Food and Drug Administration (FDA).

肌肉活检中的mRNA敲低，支持每季度给药的可能性。ABX1100已获得美国食品和药物管理局（FDA）的孤儿药物指定和罕见儿科疾病状态。

About Aro Biotherapeutics

关于Aro生物治疗学

Aro Biotherapeutics is a biotechnology company working to develop potent and versatile tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly owned pipeline of Centyrin-based therapeutic candidates for tissue-specific targeting of therapeutics for a diverse set of diseases.

Aro Biotherapeutics是一家生物技术公司，致力于开发有效且多功能的组织靶向遗传药物，其平台基于一种名为Centyrins的专有蛋白质技术。该公司正在开发一条全资拥有的基于Centyrin的候选治疗药物管道，用于针对多种疾病的组织特异性靶向治疗。

For more information, visit .

有关更多信息，请访问。

www.arobiotx.com

www.arobiotx.com

.

.